Advances in Brief

Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses

Lorne J. Brandes, Randi J. Arron, R. Patricia Bogdanovic, Jianguo Tong, Cheryl L. F. Zaborniak, Georgina R. Hogg, Robert C. Warrington, Wei Fang, and Frank S. LaBella

Departments of Medicine [L. J. B., J. B., F. S. L.], and Pathology [G. R. H.], Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0W3; Manitoba Institute of Cell Biology, Winnipeg, Manitoba R3E 0V9 [L. J. B., R. J. A., R. P. B., J. T., C. L. F. Z.]; and Department of Biochemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 0W0 [R. C. W., W. F.], Canada

Abstract

Tricyclic antidepressants, such as amitriptyline (Elavil), and the nontricyclic agent, fluoxetine (Prozac), bind to growth-regulatory intracellular histamine receptors, associated with anti-estrogen binding sites in microsomes and nuclei. The prototype anti-estrogen binding site/intracellular histamine receptor ligand, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine HCl, inhibits normal cell proliferation in vitro but stimulates tumor growth in vivo. Because of their structural similarity to N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine HCl, we carried out studies to determine whether amitriptyline and fluoxetine stimulate tumor growth and/or development in rodents at concentrations relevant to the treatment of human depression (equivalent human dose range, ~100–150 mg/day for amitriptyline and ~20–80 mg/day for fluoxetine). All experiments were performed blinded. In studies of growth stimulation of transplantable syngeneic tumors, groups of mice were inoculated s.c. with C-3 fibrosarcoma cells or given i.v. or s.c. injections of B16F10 melanoma cells, followed 24 h later by daily i.p. injections of saline, amitriptyline, or fluoxetine. Tumor latency (fibrosarcoma), aggregate tumor weight (s.c. injected melanoma), or time to death from pulmonary metastasis (i.v. injected melanoma) was determined; drug-induced stimulation of DNA synthesis in C-3 fibrosarcoma cells in vitro was correlated with tumor growth acceleration in vivo. In a mammary carcinogenesis model, the effects of chronic saline, amitriptyline, or fluoxetine administration on the rate and frequency of development of mammary tumors in rats fed dimethylbenzanthracene (DMBA) were compared. Eight of 20 amitriptyline- or fluoxetine-treated mice developed fibrosarcoma tumors by day 5, as compared to none of 20 saline controls (P < 0.002). Similarly, 20 of 21 DMBA-treated rats receiving the antidepressant drugs developed 33 mammary tumors by week 15 as compared to 5 tumors in 4 of 7 DMBA-treated rats receiving saline (P < 0.001). For both models, tumor latency decreased 30–40% and, in the DMBA model, tumor frequency increased >2-fold in the antidepressant-treated rats as compared to controls. Stimulation of fibrosarcoma growth in vivo correlated with a corresponding bell-shaped drug-induced increase in DNA synthesis in vitro. While the median time to death from pulmonary metastases did not differ among groups given i.v. injections of melanoma cells, a significant (P < 0.01) stimulation of growth of s.c. injected melanoma was observed in mice receiving the antidepressants. On the basis of these findings, we suggest that: (a) properly designed epidemiological studies be carried out to determine whether antidepressant drugs adversely affect the development or course of cancer in humans; and (b) preclinical drug screening procedures should include studies of tumor promotion, in addition to carcinogenesis.

Introduction

Episodes of serious depression affect up to 5% of the general population (1) and occur with a 3-fold higher frequency in patients with cancer (2). Tricyclic antidepressant drugs and newer nontricyclic agents such as fluoxetine (Prozac) cause rapid improvement in the symptoms of depression in a majority of patients, leading to a significant decrease in the length and/or severity of debilitation (3). Effective drug therapy for depression is especially important for patients with cancer, where quality of life often is already compromised from the side effects of surgery, radiation, and chemotherapy. Although classified as antagonists of serotonin uptake, the chemical structures of tricyclics and fluoxetine are similar to that of DPPE (4), a potent ligand for AEBS which also bind tamoxifen (5).

We have shown an association of AEBS with novel intracellular HIC, thus far identified in brain (6) and platelet membranes (7), liver microsomes (8), and nuclei (9, 10). Through binding HIC, histamine functions as an intracellular second messenger in the mediation of human platelet aggregation (11, 12). Evidence is accumulating that intracellular histamine also promotes normal and malignant proliferation at HIC (6, 8), possibly by modulating lipid/eicosanoid metabolism (10, 12). In vitro, at concentrations correlating with its antagonism of [3H]histamine binding in rat liver microsomes and nuclei, DPPE inhibits DNA synthesis in normal lymphocytes stimulated to divide by concanavalin A (9) but increases DNA synthesis above an already high baseline in transformed lymphocytes or malignant cells (10). In vivo, DPPE (1–4 mg/kg) stimulates tumor growth in mice and rats; at a higher dose (32 mg/kg), it synergizes with phorbol 12-myristate 13-acetate to induce inflammation and epithelial hyperplasia in mouse epidermis (13). These changes are necessary for tumor promotion (14).

Many aryalkylamine derivatives structurally similar to DPPE, including H1 antihistamines and phenothiazine-type neuroleptics, bind with varying potencies to AEBS/HIC (14, 15). Therefore, we determined whether antidepressant agents also bind to HIC and, at human-equivalent doses, mimic DPPE to stimulate tumor growth and development in rodents. We used amitriptyline and fluoxetine because both are widely prescribed for the treatment of depression.

Materials and Methods

Drugs

Amitriptyline-HCl was purchased from Sigma Chemical Co. (St. Louis, MO). Fluoxetine-HCl was obtained as commercially available 20-mg capsules (Prozac; Eli Lilly Co., Indianapolis, IN). Capsules were opened and the powder, containing 20 mg of active drug as the soluble HCl salt and 205 mg of insoluble cellulose-type filler per capsule, was added to sterile distilled water (2 ml/capsule). The resulting emulsion was poured into a 50-ml conical polypropylene tube (Corning Glassworks, Corning, NY) and centrifuged at 2800 × g for 20 min at room

Received 4/16/92; accepted 5/13/92.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 The work is funded by grants from the Murphy Foundation, The Medical Research Council of Canada, and the National Cancer Institute of Canada.

2 To whom requests for reprints should be addressed.
temperature. The supernatant, containing 10 mg/ml fluoxetine-HCl, was decanted off and stored at 4°C until used; the drug is said to be stable for at least 6 months in solution (insert provided by Lilly).

**Binding Studies**

To assess the potency of the agents for high affinity (nm) H₁₇ sites present in the nuclear fraction, porcine liver nuclei were prepared as described previously for rat liver nuclei (9). Fresh nuclear aliquots (protein concentration, 1–1.5 mg/ml) were incubated at room temperature in the dark for 60 min with 5 nmol [³H]histamine in the presence or absence of increasing concentrations of cold histamine, amitriptyline, or fluoxetine. The reaction was terminated by centrifugation at 12,000 × g for 15 min at 4°C. Radioactivity was quantitated in a Beckman liquid scintillation counter and binding data were analyzed using the LIGAND program (17).

**Mitogenesis Studies**

To assess the in vitro potency of the agents to inhibit normal lymphocyte proliferation, fresh spleen cells (5 × 10⁶ obtained from 5-week-old BALB/c mice (Charles River, St. Constant, Quebec, Canada) were suspended in RPMI 1640 containing 2% fetal calf serum (Grand Island Biological Co., Grand Island, NY), seeded into replicate NUNC microwells to which Con A (5 µg/ml; Sigma) was added and incubated in the presence or absence of increasing concentrations of amitriptyline or fluoxetine at 37°C in an atmosphere of 5% CO₂ and 95% air. At 43 h after the addition of Con A, 0.25 nmol [³H]thymidine (6.7 Ci/mmoul; ICN Radiochemicals, Montreal, Quebec, Canada) was added to each well. After an additional 5-h incubation, the cells were washed from the wells onto filters using an automated cell sorter. The filters were placed into vials containing scintillation fluid and the radioactivity incorporated into DNA at 48 h was determined. To assess cytotoxicity as a basis for any observed antiproliferative effects, cell number (hemocytometry) and viability (trypan blue dye exclusion) were compared to values in controls treated with buffer alone and controls treated with Con A alone.

**Tumor Models**

**C-3 Fibrosarcoma Model**

*In Vivo Study.* C-3 fibrosarcoma cells (derived from H-raf-transfected 10TV-fibroblasts) injected s.c. into the shaved gluteal tissue of C3H mice grow into a palpable tumor nodule (median appearance time, 7 days; all animals usually develop tumors within 10 days) (10). In two separate experiments, groups of 10 mice were given injections of 1 × 10⁶ C-3 cells. Starting 24 h later, daily i.p. injections of saline (controls), amitriptyline (80 mg/m²; Experiment 1), or fluoxetine (40 mg/m²; Experiment 2) were administered. The cages were coded so that a second individual assessing the development of tumors was unaware of the treatment.

*In Vitro Study.* To determine the effect of the antidepressant drugs on DNA synthesis, 5 × 10⁶ C-3 cells were seeded into microwells (NUNC) containing 100 µl α-minimum essential medium supplemented with 10% fetal calf serum (Grand Island Biological Co.) and increasing concentrations (1 × 10⁻²–1 × 10⁻⁴ M) of amitriptyline or fluoxetine. Replicates of 6 microwells were used for each concentration of drug; 12 control microwells contained cells alone in the absence of drug. The cells were incubated at 37°C in an atmosphere 5% CO₂-95% air. Nineteen h later, 0.25 nmol [³H]thymidine was added to each microwell. Following an additional 5-h incubation, the cells were washed from the wells onto filters using an automated cell sorter. The filters were placed in vials containing scintillation fluid and the radioactivity incorporated into DNA was determined.

**B16f10 Melanoma Models**

B16f10 melanoma cells, injected i.v. into the tail veins of C57Bl mice, cause death (median, 16–17 days) from multiple pulmonary metastases (10). When injected s.c., tumors grow locally within 7–10 days. Groups of 10 mice were given i.v. injections of 5 × 10⁶ B16f10 cells, while groups of 5 were given s.c. injections into the gluteal region. Twenty-four h later, daily i.p. injections of saline (control), amitriptyline (30, 60, or 75 mg/m²), or fluoxetine (12, 16, 20, or 40 mg/m²) were administered. The cages were coded so that the person making the observations was not aware of the treatment. The median time to death from pulmonary metastases in the first case, or aggregate tumor wet weight at day 17 in the second case, was determined for the various treatment groups.

**DMBA-induced Mammary Carcinoma**

When administered p.o. to 150-g female Sprague-Dawley rats (Charles River), DMBA induces mammary tumors 8–16 weeks later (18). Rats were given DMBA p.o. (20 mg in 2 ml peanut oil) using a syringe connected to a hollow curved needle with a special blunt end for i.p. gavage. The rats were then divided randomly into four groups of 7–8 animals and given saline, amitriptyline (80 mg/m²), or fluoxetine (16 or 40 mg/m²) i.p. each Monday through Friday. This 5-day/week schedule was equivalent to an average daily dose of 57 mg/m² for amitriptyline and of 11.5 mg/m² or 28.5 mg/m² for fluoxetine. Once weekly for 15 weeks, each group was examined for tumors by individuals unaware of the treatment given. All tumors were measured in two dimensions. Any deaths from tumor or other causes were recorded. For humane reasons, once an entire group of rats developed tumors, all surviving rats in the group were killed by CO₂ asphyxiation.

**Statistical Analysis**

To test for significant differences among control and antidepressant-treated groups, the following statistical analyses were performed: (a) for difference in C-3 tumor latency, Fisher's exact test (yes or no for presence of tumor, day 5) was used; (b) for differences in B16f10 melanoma tumor wet weights (day 17), the Pearson correlation coefficients were calculated and linear slopes tested; and (c) for DMBA mammary carcinoma, the Kruskal-Wallis test compared the number of tumors per group at week 15.

**Results**

**Correlation of Affinity for Nuclear H₁₇ with Potency to Inhibit DNA Synthesis in Con A-stimulated Normal Lymphocytes.** Fluoxetine and amitriptyline competed for [³H]histamine binding to a high affinity species of H₁₇ in porcine liver nuclei (Fig. 1A). The dissociation constant (Kᵣ) for histamine was 3.4 ± 3.4 × 10⁻⁷ M (mean ± SEM). The inhibitory constants (Kᵢ) for fluoxetine and amitriptyline were 4.6 ± 6.5 × 10⁻⁸ M and 1.0 ± 0.8 × 10⁻⁷ M, respectively. Rank order of potency for the agents to bind H₁₇ correlated with their inhibition of Con A-stimulated DNA synthesis in normal spleen cells (Fig. 1B); the 50% inhibitory concentration for fluoxetine was 7.5 ± 2.5 × 10⁻⁷ M, and that for amitriptyline was 2.5 ± 0.5 × 10⁻⁷ M.

**Potentiation by Antidepressant Drug Treatment of C-3 Fibrosarcoma Growth.** Saline-treated C3H mice given injections of C-3 fibrosarcoma cells began to develop palpable tumors at day 6 postinjection, whereas fluoxetine-treated animals began to develop tumors by day 3, and amitriptyline-treated animals began tumor development by day 4 postinjection. In two experiments combined, 8 of 20 animals receiving the antidepressants, but no animals receiving saline, developed tumors by day 5 (Fig. 2A, P < 0.002; Fisher's exact test). By day 10, all animals including controls had tumors; however, the acceleration of tumor appearance was approximately 30% in the animals receiving amitriptyline or fluoxetine.

**Correlation of C-3 Tumor Growth Stimulation in Vivo and Increased DNA Synthesis in Vitro.** The observed in vivo acceleration of C-3 fibrosarcoma growth by 30% in animals receiving
Overall, the latency to appearance of mammary tumors in the antidepressant-treated rats was decreased 30–40%, and the frequency of tumors increased up to 2.5-fold, as compared to saline controls. Moreover, both the mean area of tumors at first presentation (Fig. 5A), and aggregate tumor area at week 14 (Fig. 5B) were markedly higher in the antidepressant-treated rats than in saline controls; the largest tumors were found in

antidepressants correlated with a similar drug-induced increase in [3H]thymidine incorporation into DNA in C-3 cells in vitro (Fig. 2B). For both agents, a bell-shaped curve (optimal concentration, 1–5 × 10^{-8} M for fluoxetine and 1 × 10^{-7} M for amitriptyline) to increase thymidine incorporation into DNA by approximately 30–40% over baseline values was observed.

Potentiation by Antidepressants of s.c. B16F10 Melanoma Growth. No difference in survival among groups was observed when melanoma cells were injected i.v.; all survived for a median of 17 days. However, when the melanoma cells were injected s.c. (Fig. 3), the groups receiving amitriptyline or fluoxetine had significantly larger tumors than controls at day 17. [For amitriptyline, Pearson correlation coefficient (r) = 0.817; P = 0.0002. For fluoxetine, r = 0.632; P = 0.006.]

Potentiation of DMBA-induced Mammary Carcinogenesis. As compared to DMBA-treated rats receiving saline, those receiving the antidepressant agents had a significant acceleration of mammary tumor growth and development; stimulation by both low and high doses of fluoxetine was similar and was more potent than amitriptyline (Fig. 4). By week 15 after DMBA administration, the antidepressant-treated rats had developed an average of 11 tumors/group or 1.67 tumors/rat [8 tumors in 5 of 6 amitriptyline-treated rats; 12 tumors in 7 of 7 fluoxetine (11.5 mg/m^2)-treated rats; 13 tumors in 8 of 8 fluoxetine (28.5 mg/m^2)-treated rats], whereas the saline-treated group had developed 5 tumors in 4 of 7 rats or 0.71 tumor/rat (P < 0.001; Kruskal-Wallis test).
animals receiving amitriptyline. Three animals (one at each dose of fluoxetine and one who received amitriptyline) died of rapid tumor progression between weeks 11 and 13; no DMBA-treated controls receiving saline died during the 15-week observation period.

In addition, 2 of the 8 DMBA-treated rats receiving amitriptyline died of apparent drug-related causes without developing tumors (1 at week 4; 1 at week 9). At autopsy, one of the rats had diffuse areas of old and new hemorrhage and erythropoieticosis in the abdominal wall, lungs, and peritoneum, with evidence of rosetting of RBC around phagocytes, suggestive of an immune reaction. The second rat showed evidence of inflammation (pleuritis/epicarditis). No drug-associated toxicity was observed in DMBA-treated animals receiving saline or either dose of fluoxetine.

Discussion

The demonstration that amitriptyline and fluoxetine inhibit normal lymphocyte proliferation in vitro and promote tumor growth in 3 of 3 rodent models in vivo raises the question of whether they could have a similar effect in humans. For example, fluoxetine (20–40 mg/day) has been associated with 21 reported cases of reactivation of herpes simplex or zoster infection (19) suggesting that, even at the lowest range of prescribed doses, it can impair normal human immune function in vivo. Since we have shown that the stimulation of DNA synthesis in C-3 fibrosarcoma cells by amitriptyline and fluoxetine occurs at somewhat lower in vitro concentrations than does their inhibition of lymphocyte mitogenesis, the potential for these agents, likewise, to promote in vivo tumor growth in humans at clinically relevant doses must be assessed.

While many epidemiological studies have addressed a possible connection between human depression and cancer incidence, mortality or outcome (20–23), the results have been conflicting. However, the only study examining the use of neuroleptics (including antidepressants, tranquilizers, and hypnotics) ante-dating the diagnosis of cancer found a significantly higher incidence of metastases at presentation, or within 1 year of diagnosis, in those patients who reported taking such drugs in the preceding 12 months (24). In view of our findings, we suggest that new epidemiological studies be carried out to ask the following questions: (a) Do depressed patients on chronic antidepressant therapy run a significantly higher risk of developing cancer than those not on antidepressants? (b) Is a putative increased risk of developing cancer from taking antidepressant drugs dependent on concomitant exposure to a tumor initiator, e.g., cigarette smoke? (c) Do antidepressant drugs accelerate the clinical course if cancer is already present?

Finally, our studies also raise an equally important question concerning the adequacy of using tests only for carcinogenicity in preclinical toxicology studies. Information provided on fluoxetine states that no carcinogenesis was observed in mice receiving 5–9 times the human-equivalent dose of drug for 24 months (25); moreover, there was no evidence of mutagenicity in the Ames test or in assays for induction of double-stranded DNA breaks (25). However, while undoubtedly of predictive value, standard tests for mutagenesis/carcinogenesis appear to miss the potential of drugs to act as tumor promoters when cancer is already present, or to accelerate the development of malignancy in the presence of chemical or viral initiators.
action at anti-estrogen binding sites was considered. Our observations with antidepressant drugs are consistent with this postulate, since, like amitriptyline and fluoxetine bind AEBS/Hu and ac the estrogen receptor. Nature (Lond.), 288: 273–275, 1980.


References


Acknowledgments

We thank Sophie Didych and Carroll Powney for their help in preparing the manuscript, and Mary Cheang, M. Math., Department of Community Health Services, University of Manitoba, for statistical analysis.

Addendum

Recently, tamoxifen was reported to accelerate the growth of hormonally independent mammary carcinoma induced by DMBA in rats (26). Although the mechanism was not identified with certainty, an action at anti-estrogen binding sites was considered. Our observations with antidepressant drugs are consistent with this postulate, since, like tamoxifen, both amitriptyline and fluoxetine bind AEBS/Hc and accelerate DMBA-induced mammary tumor growth.

Fig. 5. Mean area (bars, SE) of tumors at first detection (A) and aggregate tumor area (week 14) (B) in DMBA-treated rats receiving chronic administration of saline, amitriptyline (11.5 mg/kg), or fluoxetine (28.5 mg/kg). The values include aggregate tumor areas in 3 rats at the time of death prior to week 14 (1 amitriptyline; 1 at each dose of fluoxetine).

STIMULATION OF MALIGNANT GROWTH BY ANTIDEPRESSANT DRUGS
Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses


Updated version

Access the most recent version of this article at:

http://cancerres.aacrjournals.org/content/52/13/3796

---

**E-mail alerts**

Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.